XML 63 R41.htm IDEA: XBRL DOCUMENT v3.6.0.2
Description of Business - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 09, 2016
Jan. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Net revenue from collaboration         $ 171,965,000      
Gain on extinguishment of debt         72,024,000 $ (1,049,000)    
Accumulated deficit     $ (2,737,565,000)   (2,737,565,000) (2,863,229,000)    
Cash and cash equivalents     22,895,000   22,895,000 59,074,000 $ 120,841,000 $ 70,790,000
Loan Arrangement                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Amount available for future borrowings     30,100,000   30,100,000 $ 30,100,000    
License and Collaboration Agreement with Sanofi                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Gain on extinguishment of debt $ 500,000              
Insulin Put                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Net revenue from collaboration         10,200,000      
Principal stockholder | Loan Arrangement                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Amount available for future borrowings     30,100,000   30,100,000      
Aventisub LLC                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Outstanding loan balance forgive $ 72,000,000              
Sanofi-Aventis Deutschland GmbH | License and Collaboration Agreement with Sanofi                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Net revenue from collaboration     10,200,000 $ 161,800,000 172,000,000      
Gain on extinguishment of debt     72,000,000          
Up-front fee         150,000,000      
Sanofi-Aventis Deutschland GmbH | Insulin Put | License and Collaboration Agreement with Sanofi                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Net revenue from collaboration         19,400,000      
Sanofi-Aventis Deutschland GmbH | Subsequent Event | Put Option                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Payment for insulin put option   $ 30,600,000            
Deerfield | Senior convertible notes due December 31, 2019 | Minimum | Less portion of commitment asset                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Available amount of credit facility under covenant restrictions     $ 25,000,000   $ 25,000,000